Outcome in community-acquired pneumonia (CAP) is adversely aff ected by increasing severity of illness, comorbidity and age. Organisational factors such as timely administration of appropriate antibiotics, prompt admission to critical care and adherence to antibiotic policies, however, are also important in infl uencing outcome [1] [2] [3] . Combination therapy with two antimicrobial agents seems superior to monotherapy in severe CAP, and this approach is recommended by a number of organisations [4, 5] . Th e Infectious Diseases Society of America/American Th oracic Society guidelines suggest therapy with a β-lactam antibiotic, with the addition of either a macrolide or fl uoroquinolone antibiotic [4] , whilst the British Th oracic Society recommends initiating a β-lactam/macrolide antibiotic combination [5] .
Martin-Loeches and colleagues recently conducted a prospective, observational cohort, multicentre study involving 218 mechanically ventilated CAP patients to see what eff ect diff erent antibiotic combinations had on mortality [6] . Th ese investigators reported that the addition of a macrolide, but not a fl uoroquinolone, to standard antibiotic therapy was associated with reduced mortality in patients admitted to critical care with CAP. Death in critical care occurred in 26.1% of individuals receiving combi nation therapy with a macrolide, compared with 46.3% in those receiving fl uoroquinolones [6] . Th ese results support data from other observational studies that suggest β-lactam/macrolide combinations off er a survival advantage in severe CAP. Th is body of data is not scientifi cally robust enough, however, to adequately answer the question of whether adding a macrolide to a β-lactam confers a survival advantagethis will only be satisfactorily addressed by a large prospective random ised control trial.
In addition to activity against atypical bacteria, macrolides have ubiquitous immunomodulatory eff ects. Speculat ing how this group of drugs might off er a survival advantage when added to a β-lactam is therefore of interest, and several plausible mechanisms exist. Treatment of undiagnosed atypical pneumonia could occur since 53% of patients in the reported study had no microbiological diagnosis [6] ; however, this seems unlikely as one might expect fl uoroquinolones to be equally eff ective [7] . More over, studies limited to pneumo coccal disease demon strate that addition of a macrolide improves survival [8] . It also seems improbable that synergistic killing is responsible, as equivalency with fl uoroquino lones would be expected.
Many researchers have focused on the pleiotropic immunomodulatory eff ects [9] observed with macrolides as the reason why these agents may be benefi cial in CAP. Macrolides, at doses lower than those required for antibacterial activity, alter the production of cytokines and chemokines, and reduce cellular infi ltrates and mucous production [9] . Th e immunomodulatory eff ects of macrolides are illustrated by diff use panbronchiolitis. A chronic progressive lung disease found largely in Japan, diff use panbronchiolitis is characterised by mixed restrictive and obstructive pulmonary function, interstitial infi ltrates and Pseudomonas aeruginosa infection. Long-term, low-dose macrolide treatment improves lung function and increases 10-year survival rates from around 15 to 90% [9] .
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Macrolides and community-acquired pneumonia: is quorum sensing the key? Macrolides are now being explored in new therapeutic strategies for a wide range of pulmonary and extrapulmonary conditions, including asthma, cystic fi brosis, rhinosinusitis, infl ammatory bowel disease, psoriasis and rosacea [9] . Clearly immunomodulatory eff ects could be important in altering mortality in CAP, but these drugs also have direct eff ects on bacteria through inhibiting quorum sensing.
Quorum sensing describes bacterial cell-to-cell communication that occurs as a function of changing cell density. Th ese communication pathways are important in the pathogenesis of bacterial species causing human disease, including Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli and P. aeruginosa [10, 11] . Quorum-sensing bacteria produce and release signal molecules or autoinducers, which regulate gene expression within the bacterial population and are closely linked to both biofi lm formation and expression of virulence factors. Biofi lms are structured populations of bacteria within a polysaccharide matrix, and these growth forms are more resistant to antibiotics. Th e discovery of biofi lms as an entity did not occur until the late 1970s, and they are often still only considered in the context of chronic or device-associated infections; however, pneumonia caused by S. pneumoniae exists as a biofi lm in lung tissue [11] . Acute bacterial infections associated with biofi lm formation might also be relatively common. One of the diagnostic criteria for biofi lm infection is a culture-negative result despite a clinically documented infection [12] , a situation encountered in 30 to 50% of severe sepsis and septic shock [6] .
Macrolides at subminimum inhibitory concentrations have been demonstrated to antagonise quorum sensing in P. aeruginosa, resulting in diminished virulence, biofi lm formation and oxidative stress response [13] . Significantly, inhibition of quorum sensing reduces pathogenicity of bacteria and impedes formation of antibiotic-resistant biofi lms, and therefore off ers an attractive mechanism whereby the addition of a macrolide could reduce mortality in CAP [6] . If macrolides do confer additional effi cacy because of immunomodulatory eff ects or inhibition of quorum sensing, or both, one might expect them to be an eff ective therapeutic strategy applicable to many other infections encountered in critically ill patients. Indeed, the addition of clarithromycin to patients with ventilator-associated pneumonia accelerated resolution of pneumonia and weaning from mechanical ventilation [14] .
It may be possible to approach the question of whether immunomodulation or inhibition of quorum sensing is more important in reducing mortality experimentally. Lesprit and colleagues described the important role of P. aeruginosa quorum sensing in rat pulmonary infection using the virulent wild-type strain P. aeruginosa PAO1 and the less virulent mutant strain P. aeruginosa PAOR with a defi cient quorum-sensing pathway [15] . Using this model system it would be benefi cial to examine whether macrolides act predominantly through disrupting quorum sensing, as one would then expect to see little reduction in mortality caused by a large inoculum of the mutant PAOR but a signifi cant eff ect on pneumonia caused by a smaller dose of the wild-type PAO1.
At a time when few new antimicrobial agents are being commercially developed for clinical use and the burden of infection caused by multiresistant bacteria is increasing, the need for novel approaches to the management of infection is essential. Quorum sensing determines both bacterial virulence and biofi lm formation; it is a common pathway for pathogens and represents an attractive new target for the development of drugs in the fi ght against infection [10] .
